Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian kidney disease, affecting approximately one in 1,000 births and accounting for 5% of end-stage kidney disease in developed countries. The pathophysiology of ADPKD is strongly linked to metabolic dysregulation, which may be secondary to defective polycystin function. Overweight and obesity are highly prevalent in patients with ADPKD and constitute an independent risk factor for progression. Recent studies have highlighted reduced AMP-activated protein kinase (AMPK) activity, increased mammalian target of rapamycin (mTOR) signaling, and mitochondrial dysfunction as shared pathobiology between ADPKD and overweight/obesity. Notably, mTOR and AMPK are two diametrically opposed sensors of energy metabolism that regulate cell growth and proliferation. However, treatment with the current generation of mTOR inhibitors is poorly tolerated due to their toxicity, making clinical translation difficult. By contrast, multiple preclinical and clinical studies have shown that pharmacological activation of AMPK provides a promising approach to treat ADPKD. In this narrative review, we summarize the pleiotropic functions of AMPK as a regulator of cellular proliferation, macromolecule metabolism, and mitochondrial biogenesis, and discuss the potential for pharmacological activation of AMPK to treat ADPKD and obesity-related kidney disease.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian kidney disease (lifetime prevalence of at least 1:1,000 births), accounting for almost 5% of all end-stage kidney disease (ESKD) in developed countries (Harris and Torres, 2009; Lanktree et al., 2018). Mutations in PKD1 (encoding polycystin 1 or PC1) and PKD2 (encoding polycystin 2 or PC2) account for 70%–85% and 15%–30% of genetically resolved cases, respectively (Rossetti et al., 2007; Barua et al., 2009; Cornec-Le Gall et al., 2013; Heyer et al., 2016; Hwang et al., 2016). ADPKD is characterized by the slow expansion of innumerable cysts in the kidneys with inflammation and fibrosis as defining features associated with advanced kidney failure in a high proportion of affected individuals (Grantham, 2008; Harris and Torres, 2009). Currently, only tolvaptan, an antagonist of vasopressin V2 receptors is approved to treat ADPKD (Irazabal et al., 2011; Torres et al., 2012; Torres et al., 2017). However, tolvaptan is an expensive drug with serious side effects such as significant polyuria, nocturia, and potential liver toxicity (Irazabal et al., 2011). Hence, there is a pressing need for novel interventions that are safe and effective for patients with ADPKD.
The kidneys are among the most metabolically active organs in the body: although they only represent 0.5% of the human body mass, they consume 10% of the body’s oxygen (Nowak and Hopp, 2020). Consequently, the modulation of key metabolic pathways has generated much interest in the field of ADPKD. The pathophysiology of ADPKD was shown to be strongly linked to metabolic dysregulation, which may occur secondary to defective polycystin function (Distefano et al., 2009; Zheng et al., 2009). Metabolic reprogramming, mediated through novel or repurposed drugs, or through dietary changes (e.g., caloric restriction), holds the promise of improving the course of cystic disease (Nowak and Hopp, 2020; Menezes and Germino, 2019; Podrini et al., 2020; Haumann et al., 2020; Pickel et al., 1093; Warner et al., 2016). Recently, overweight and obesity were demonstrated to be independent predictors of ADPKD progression (Nowak et al., 2018; Nowak et al., 2021). This suggests that weight loss could provide a strategy for controlling cyst growth. In this narrative review, we highlight the shared pathobiology between ADPKD and overweight/obesity. In particular, we focus on the interaction between mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) signaling, and their biological functions in the kidneys. mTOR and AMPK are two diametrically opposed sensors of energy metabolism that play a key role in regulating cell growth and proliferation (Steinberg and Kemp, 2009). We summarize the current knowledge on the function of AMPK as a regulator of cellular energy metabolism and modulator of tissue inflammation, and the preclinical and clinical evidence supporting pharmacological activation of AMPK to treat ADPKD and improve obesity-related kidney disease.
Obesity is clinically associated with more severe autosomal dominant polycystic kidney disease
The World Health Organization (WHO) defines overweight and obesity in adults as a body mass index (BMI) ≥25 kg/m2 and ≥30 kg/m2, respectively. The global prevalence of obesity in adults was 13% in 2016 (15% of women and 11% of men), a threefold increase since 1975 (https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight, updated 9 June 2021). Worryingly, between 1975 and 2016, the global prevalence of obesity in children and adolescents also increased from 0.7 to 5.6% in girls and from 0.9 to 7.8% in boys (Abarca-Gómez et al., 2017). The rate of increase in BMI since 2000 has slowed down in high-income countries, but has accelerated in some regions of the developing world (NCD Risk Factor Collaboration, 2016). Epidemiologic studies have highlighted high BMI as a risk factor for numerous chronic conditions, including cardiovascular disease, diabetes mellitus, chronic kidney disease (CKD), cancer, and musculoskeletal disorders (The GBD 2015 Obesity Collaborators Ashkan Afshin et al., 2017). Obesity results from energy intake exceeding energy expenditure, which leads to adipose tissue expansion (Rosen and Spiegelman, 2006). Contributors to this energy imbalance are numerous, including genetic, epigenetic, physiological, environmental, sociocultural, and behavioral factors (Fall et al., 2017; Gadde et al., 2018).
Although it was noted almost 20 years ago that the number of patients with ADPKD and concomitant obesity has been increasing, only recently has the impact of high BMI on ADPKD been explored (Schrier et al., 2003). Nowak et al. (2018) observed that, in 441 non-diabetic subjects with early-stage ADPKD, more than half of the cohort was overweight or obese. Importantly, BMI was independently associated with a greater annual percent change in total kidney volume (TKV). Obesity, compared to normal weight, was also independently associated with a greater decline in eGFR (Nowak et al., 2018). A later study confirmed some of these observations using patients at high risk of rapid progression from the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial (Nowak et al., 2021).
Obesity commonly co-occurs with the metabolic syndrome. The latter is characterized by a cluster of cardiometabolic risk factors including abdominal obesity, high blood pressure, elevated fasting blood glucose, and dyslipidemia (i.e., high triglycerides and low HDL cholesterol) (Alberti et al., 2009). Pietrzak-Nowacka et al. (2009) found that hypertension was the main component of the metabolic syndrome to correlate with ADPKD, whereas BMI and waist-to-hip ratio did not differ compared to age- and gender-matched controls. Fasting glucose levels were higher in patients with ADPKD, but the difference in blood glucose did not persist after an oral glucose tolerance test. However, these findings must be interpreted with caution, as BMI was not adjusted for kidney and liver volume. Reed et al. (2012) described larger kidney volumes in patients with ADPKD and type 2 diabetes, compared to those with ADPKD alone. However, since BMI was higher on average in the group with type 2 diabetes, it remains unclear whether it was the dysglycemia or elevated BMI that contributed to the results.
Several signaling pathways relevant to obesity, such as AMPK, are also known to play a major role in the pathobiology of ADPKD. The correlation between BMI and cystic disease progression may be explained by a number of mechanisms including metabolic dysregulation related to nutrient availability, hormonal changes such as hyperinsulinemia, low-grade chronic inflammation, or any combination thereof. Examining the pathways common to both obesity and ADPKD may help generate hypotheses to support future mechanistic studies (Nowak et al., 2018).
mTORC1 plays a major role in the pathophysiology of autosomal dominant polycystic kidney disease
The mTOR protein is a serine/threonine kinase central to two different complexes: mTOR complex 1 (mTORC1), which includes six protein components, and mTOR complex 2 (mTORC2), which includes seven. mTORC1 responds to available amino acids and oxygen, growth factors, DNA homeostasis, and cellular energy levels to activate cell proliferation by enhancing protein synthesis, stimulating the cell cycle, and inhibiting autophagy. On the other hand, mTORC2 is involved in the organization of the actin cytoskeleton and regulates mTORC1 function (Laplante and Sabatini, 2012; Yoon, 2017; Boutouja et al., 2019). mTORC1 is downregulated by AMPK, which phosphorylates and inactivates the Raptor component of the complex, and phosphorylates and activates tuberous sclerosis complex 2 (TSC2), a negative regulator upstream of mTORC1 (Figure 1). (Boutouja et al., 2019) mTORC1 signaling promotes protein synthesis by phosphorylating the translational regulators S6 kinase 1 (S6K1) and 4E-binding protein 1 (4E-BP1) (Laplante and Sabatini, 2012). Moreover, mTORC1 is a potent suppressor of autophagy via phosphorylation and inhibition of unc-51-like kinase 1 (ULK1) (Laplante and Sabatini, 2012). mTORC1 is activated in the kidney proximal tubules of obese mice fed a high-fat diet (HFD), and long-term lipid overload was recently shown to induce lysosomal dysfunction, impaired autophagy, and susceptibility to kidney injury (Yamahara et al., 2013; Yamamoto et al., 2017). Enhanced mTORC1 signaling was repeatedly confirmed in the epithelium of kidney cysts, stimulating cell proliferation and inhibiting autophagy, which are both involved in the pathogenesis of ADPKD; multiple preclinical studies of mTORC1 inhibitors sirolimus (rapamycin) and everolimus showed some benefit in rodent models (Table 1). (Tao et al., 2005; Shillingford et al., 2006; Wahl et al., 2006; Wu et al., 2007; Zafar et al., 2009; Shillingford et al., 2010; Zafar et al., 2010; Song et al., 2020)
FIGURE 1
TABLE 1
| Agent | Mechanism of action | Study | Experimental model | Evidence |
|---|---|---|---|---|
| Sirolimus | mTOR inhibitor | Riwanto et al. (2016) | Human ADPKD cells | ↓mRNA expression of glycolytic genes and ↓lactate |
| Tao et al. (2005) | Han:SPRD rat | ↓cyst burden, ↑kidney function | ||
| Wahl et al. (2006) | Han:SPRD rat | ↓cyst burden, ↑kidney function | ||
| Shillingford et al. (2006) | orpk-rescue mouse | ↓cyst burden | ||
| Zafar et al. (2009) | Han:SPRD rat | ↓cyst burden, ↑kidney function | ||
| Zafar et al. (2010) | aPkd2WS25/- mouse | ↓cyst burden | ||
| Shillingford et al. (2010) | aPkd1cond/cond:Nestincre mouse | ↓cyst burden, ↑kidney function, ↓fibrosis | ||
| Everolimus | mTOR inhibitor | Wu et al. (2007) | Han:SPRD rat | ↓cyst burden, ↑kidney function |
| 2DG | Glycolysis inhibitor/AMPK agonist | Rowe et al. (2013) | • aPkd1flox/-:Ksp-Cre mouse; • aPkd1V/V mouse | ↓cyst burden ↓cyst burden |
| Riwanto et al. (2016) | Han:SPRD rat | ↓cyst burden, ↑kidney function | ||
| Chiaravalli et al. (2016) | aPkd1ΔC/floxTmCre mouse (inactivation of Pkd1 at two time points) | ↓cyst burden (both medium- and long-term models), ↑kidney function and ↓inflammation (long-term model) | ||
| Lian et al. (2019) | aInducible deletion of PKD1 in minipig | ↓cyst burden, ↑kidney function | ||
| Metformin | AMPK agonist | Riwanto et al. (2016) | Human ADPKD cells | ↓mRNA expression of glycolytic genes and ↓lactate |
| Takiar et al. (2011) | • MDCK cells cultured with forskolin/IBMX; • Embryonic C57/B6 mouse kidneys cultured with cAMP; • aPkd1flox/-:Ksp-Cre mouse; • aPkd1flox/-:pCX-CreER mouse | ↓cyst size ↓cyst area ↓cyst burden ↓cyst burden | ||
| Lian et al. (2019) | aInducible deletion of PKD1 in minipig | ↓cyst burden, ↑kidney function | ||
| Chang et al. (2017) | aMorpholino knock-down of pkd2 in zebrafish embryo | ↓pronephric cyst burden and ↓inflammation | ||
| Pastor-Soler et al. (2022) | aHomozygous R3277C point mutation in mouse Pkd1 | ↓cyst burden, ↑kidney function | ||
| Salsalate | AMPK agonist | Leonhard et al. (2019) | aiKsp-Pkd1del conditional knock-out mouse | ↓cyst burden, ↑kidney function |
| Fenofibrate | PPARα agonist | Hajarnis et al. (2017) | aPkd2 knock-out mouse | ↓cyst burden |
| Lakhia et al. (2018) | aPkd1RC/RC mouse | ↓cyst burden, ↑kidney function, ↓inflammation |
In vitro and animal studies investigating metabolic agents of interest in the treatment of ADPKD.
2DG: 2-deoxy-D-glucose; cAMP: cyclic AMP; IBMX: 3-isobutyl-1-methylxanthine; MDCK: Madin-Darby canine kidney.
Orthologous animal model.
Interestingly, mTORC1 signaling also stimulates aerobic glycolysis, also known as the Warburg effect, by enhancing the translation of critical mediators such as c-Myc and hypoxia-inducible factor 1α (HIF-1α), which upregulate many glycolytic genes (Figure 1). (Osthus et al., 2000; Thomas et al., 2006; Lee et al., 2020) Aerobic glycolysis refers to the predominant cellular use of glycolysis to generate ATP, as opposed to the more metabolically efficient oxidative phosphorylation, even in the presence of abundant oxygen (Vander Heiden et al., 2009). Aerobic glycolysis is an important metabolic feature of proliferating cells (such as cancer cells) that facilitates replication of the cellular biomass (nucleotides, amino acids, and lipids) by providing specific molecular components (e.g., reduced nicotinamide adenine dinucleotide phosphate or NADPH) (Vander Heiden et al., 2009). Importantly, the Warburg effect is also a feature of cystic epithelia in ADPKD. Sirolimus reduced the expression of glycolytic genes in human ADPKD cells (Riwanto et al., 2016). Studies in rodents and minipigs showed that inhibiting glycolysis with 2-deoxy-D-glucose (2DG) improved cystic disease (Table 1) (Rowe et al., 2013; Rowe and Boletta, 2014; Chiaravalli et al., 2016; Riwanto et al., 2016; Lian et al., 2019).
However, in studies of patients with ADPKD, treatment with sirolimus and everolimus has produced disappointing results (Table 2). In randomized controlled trials of either sirolimus or everolimus, beneficial effects on TKV were short-lived or confounded by flaws in study design (e.g., small sample size or short follow-up) (Perico et al., 2010; Serra et al., 2010; Walz et al., 2010; Ruggenenti et al., 2016). In two of these studies, side effects from sirolimus prompted investigators to reduce the delivered doses below those intended, therefore potentially jeopardizing the effectiveness of the drug (Perico et al., 2010; Serra et al., 2010). A sirolimus trial including patients with advanced CKD was terminated after 1 year due to accelerated disease progression and multiple side effects (Ruggenenti et al., 2016). Lower-dose sirolimus might be a viable alternative, with evidence of fewer side effects (Braun et al., 2014). In addition, the study protocol for a randomized controlled trial of pulsed (weekly) oral sirolimus was published previously, although at this time the results remain unknown (NCT02055079) (Riegersperger et al., 2015). In conclusion, pharmacological inhibition of mTORC1 at present is not a promising clinical option for the treatment of ADPKD.
TABLE 2
| Agent | Mechanism of action | Study | Evidence | Advantages/Disadvantages of the therapy |
|---|---|---|---|---|
| Sirolimus | mTOR inhibitor | Serra et al. (2010) RCT | Inconclusive (low number of patients, short follow-up, no difference in TKV) | • Multiple side effects • Accelerated disease progression in patients with advanced CKD |
| Perico et al. (2010) RCrT | ||||
| Braun et al. (2014) RCT | ||||
| Ruggenenti et al. (2016) RCT | ||||
| Ongoing trial: NCT02055079 (status unknown) | ||||
| Everolimus | mTOR inhibitor | Walz et al. (2010) RCT | Inconclusive (effect on TKV not maintained) | • Multiple side effects |
| Metformin | AMPK agonist | Sorohan et al. (2019) SA | Good tolerability, studies not designed to assess change in kidney function | • Well-known, inexpensive drug• G-I side effects • Risk of lactic acidosis with lower kidney function |
| Perrone et al. (2021) RCT | ||||
| Brosnahan et al. (2022) RCT | ||||
| Ongoing trials: NCT03764605 (status unknown); NCT04939935 (not yet recruiting) |
Clinical studies investigating metabolic agents of interest in the treatment of ADPKD.
CKD: chronic kidney disease; RCT: randomized controlled trial; RCrT: randomized crossover trial; G-I: gastro-intestinal; SA: single-arm pilot study; TKV: total kidney volume.
AMP-activated protein kinase is a potential therapeutic target in both obesity and autosomal dominant polycystic kidney disease
AMPK, an important integrator of multiple pathways, is a therapeutic target of particular interest. AMPK functions as a major molecular sensor of cellular energy, responding to energy depletion by switching on catabolic pathways and switching off anabolic pathways (Hardie et al., 2012). As summarized in a recent review, AMPK plays a central role in the pathophysiology of ADPKD by modulating multiple biological processes, including cellular proliferation, autophagy, solute transport, metabolism and mitochondrial homeostasis in the kidney, all of which are important for cystogenesis (Figure 2). (Song et al., 2020)
FIGURE 2
AMPK is a heterotrimer consisting of a catalytic α-subunit, a regulatory β-subunit, and a regulatory γ-subunit assembled in a 1:1:1 ratio (Hallows et al., 2010; Hardie et al., 2012). Subunits have multiple isoforms (α1, α2, β1, β2, γ1, γ2, and γ3), each encoded by a different gene with tissue-specific expression and activity (Steinberg and Kemp, 2009). Isoform frequency in the kidney is species-dependent; for instance, the β1 subunit is present in 93, 96, and 64% of kidneys of C57BL/6J mice, Wister Han rats, and humans, respectively (Fraser et al., 2005; Salatto et al., 2017). AMPK is activated by rising concentrations of AMP relative to ATP. Upon binding to AMP, AMPK is phosphorylated in its catalytic loop (at residue Thr172) by one of the three upstream AMPK kinases (Figure 1): liver kinase B1 (LKB1), Ca2+/calmodulin-activated protein kinase kinase β (CaMKKβ), or Tak1 kinase (TAK1) (Steinberg and Kemp, 2009; Hallows et al., 2010; Hardie et al., 2012).
It has been suggested that AMPK signaling may be suppressed with obesity (Figure 3) (Steinberg and Kemp, 2009). AMPK activity is reduced in the heart, liver, and skeletal muscle in genetic models of rodent obesity (Barnes et al., 2002; Yu et al., 2004; Wangyun and Unger, 2005; Sriwijitkamol et al., 2006; Steinberg et al., 2006). On the other hand, AMPK activity is not always altered in the tissues of animals with HFD-induced obesity, nor is it altered in the skeletal muscle of obese humans (Steinberg et al., 2004; Bandyopadhyay et al., 2006; Martin et al., 2006). Nevertheless, AMPK activity is strongly downregulated in the adipose tissue of obese humans (Galic et al., 2011). This inhibition of AMPK may be related to low-grade chronic inflammation and high levels of glucose and insulin, which collectively suppress kinase activity through several distinct mechanisms (Steinberg et al., 2006; Valentine et al., 2014; Zhao et al., 2018; Jiang et al., 2021). With respect to lipid metabolism, AMPK inhibits acetyl-CoA carboxylase 1 and 2 (ACC1 and ACC2), thereby increasing fatty acid oxidation and suppressing fatty acid synthesis; AMPK also inhibits hydroxy-3-methylglutaryl-CoA reductase (HMGCR), therefore suppressing cholesterol synthesis (Steinberg and Kemp, 2009; Steinberg and Carling, 2019). This may be of special importance to the pathogenesis of lipid-induced nephrotoxicity, a type of ectopic lipid accumulation associated with obesity (Figures 2, 3) (van Herpen and Schrauwen-Hinderling, 2008). Indeed, AMPK was demonstrated to be an important pathway in HFD-associated kidney disease, described by the authors as glomerulomegaly with increased mesangial matrix, inflammation, and albuminuria. Specifically, HFD feeding in mice markedly decreased phosphorylation of glomerular AMPKα. Treating C57BL/6J mice with the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) for 1 week restored AMPK activity, preventing kidney hypertrophy and macrophage infiltration (Declèves et al., 2011). However, it should be noted that AICAR has a number of AMPK-independent effects, and can lower blood pressure and blood glucose; as such, these results should be interpreted with caution. Interestingly, in a later study, HFD-induced renal injury was further described as vacuolated proximal tubular cells with loss of the brush border, suggesting tubular damage (Declèves et al., 2014). Glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide was shown to restore AMPK signaling, and reduce glomerular size, glomerulosclerosis, and interleukin levels in obese Sprague-Dawley rats fed a HFD (Wang et al., 2018). Therefore, obesity-related kidney disease associated with lipid deposits appears to be mediated by suppressed AMPK activity, affecting both the glomerular and tubular compartments of the kidney.
FIGURE 3
Following the initial preclinical research examining the role of mTORC1 in ADPKD, several studies focused on its inhibitor AMPK. More than 10 years ago, metformin, an AMPK agonist, was used to suppress cystogenesis in an in vitro model, an ex vivo model, and two mouse models of ADPKD (Table 1). Metformin was shown to reduce mTOR signaling in the kidneys of the two mouse models (Takiar et al., 2011). The authors concluded that AMPK activation may alleviate cystic disease by two main mechanisms: by inhibiting the pro-proliferative mTOR pathway and the cystic fibrosis transmembrane conductance regulator (CFTR) channel that mediates fluid secretion into cysts (Takiar et al., 2011). In a subsequent study, AMPK phosphorylation was demonstrated to be reduced in fibroblasts isolated from Pkd1 knock-out mouse embryos compared to wild-type cells (Rowe et al., 2013). In addition to its inhibitory effect on mTORC1, AMPK may potentially suppress cell proliferation in cysts by phosphorylating and activating eukaryotic elongation factor 2 kinase (eEF2K), which plays an essential role in inhibiting protein synthesis (Steinberg and Kemp, 2009). The distribution of AMPK in the kidney further supports its role in cystogenesis, as phosphorylated AMPK was detected on the basolateral surface of the rat collecting duct, which in the adult kidney is a major site of cyst formation (Fraser et al., 2005; Harris and Torres, 2009). While the molecular cause for suppressed AMPK activity in ADPKD remains unclear, Pkd1 knock-out mouse embryonic fibroblasts (MEFs) displayed increased activity of the extracellular signal-regulated kinase (ERK). In the same experiment, ERK inhibited TSC2, which may contribute to mTORC1-mediated cell proliferation (Distefano et al., 2009). Although ERK has been postulated to suppress the LKB1-AMPK axis in Pkd1 knock-out MEFs, this pathway remains to be confirmed (Rowe et al., 2013).
Pharmacological agonists of AMP-activated protein kinase show promise in the treatment of autosomal dominant polycystic kidney disease
Several drugs that activate AMPK may have applications in the treatment of APDKD. Metformin, an oral agent commonly used to treat type 2 diabetes, activates AMPK indirectly by inhibiting complex I of the electron transport chain, leading to a drop in cellular ATP and an increase in AMP (Rena et al., 2017). In an in vitro model of kidney cystogenesis, metformin inhibited the expression of glycolytic genes and lowered lactate production (Riwanto et al., 2016). Several animal studies have demonstrated that metformin improves cystic disease (Table 1). In two Pkd1 knock-out mouse models, metformin ameliorated cystic kidney disease (Takiar et al., 2011). Moreover, in MEFs isolated from Pkd1 knock-out embryos, phosphorylated AMPK was reduced compared to wild-type cells; treating the mutant cells with metformin or AICAR restored AMPK activity (Rowe et al., 2013). In a minipig model and a zebrafish model, metformin similarly activated AMPK, thereby reducing cyst formation (Chang et al., 2017; Lian et al., 2017; Lian et al., 2019). Importantly, metformin improved disease severity in the Pkd1 RC/RC mouse model, which approximates the slow progression of cystic disease in humans (Pastor-Soler et al., 2022). Pilot metformin studies in human populations with ADPKD did not show a benefit on eGFR, although the drug was well tolerated in both a single-arm study and two randomized controlled trials (Table 2). (Sorohan et al., 2019; Perrone et al., 2021; Brosnahan et al., 2022) Two additional trials of metformin in ADPKD are ongoing in Italy and Australia (NCT03764605 and NCT04939935, respectively).
Canagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes, has the off-target effect of activating AMPK indirectly by inhibiting mitochondrial respiration (Leonhard et al., 2019). By contrast, salicylate derived from the pro-drug salsalate activates AMPK directly by binding to its β-subunit. Salsalate, unlike aspirin, interacts little with the cyclooxygenase pathway, which limits the occurrence of gastrointestinal and bleeding side effects (Anderson et al., 2014). In a collaboration between our group and Leiden University, salsalate alone or in combination with metformin was shown to decrease kidney weight and improve survival from ESKD in an adult-onset conditional Pkd1 knock-out mouse model. Conversely, treatment was ineffective with metformin alone, canagliflozin alone, or metformin in combination with canagliflozin (Leonhard et al., 2019). In this study, the method of administration of metformin was different (oral) from that used by Takiar et al. (2011) (intra-peritoneal), but the dosage was identical; the relatively low oral bioavailability of metformin (∼30–60%) likely limited its action in the kidneys (Padwal et al., 2011). Although the same oral metformin dosage was used in the Pkd1 RC/RC mouse study, the longer duration of treatment in the latter may explain the improvement seen in kidney disease (Pastor-Soler et al., 2022). To our knowledge, there are currently no clinical trials of salsalate in ADPKD.
Lastly, AMPK-activating resveratrol, a polyphenol that also activates sirtuin 1 (SIRT1), was used to reverse diabetic nephropathy and prevent lipid-induced nephrotoxicity in db/db mice (Kim et al., 2013). Nonetheless, because treatment with a pan-sirtuin inhibitor (nicotinamide) and a SIRT1-specific inhibitor (EX-527) delayed cyst growth in Pkd1 knock-out mouse embryonic kidneys, Pkd1 conditional knock-out postnatal mice, and Pkd1 hypomorphic mice, it is unclear whether sirtuin 1 is an interesting drug target in combined obesity and ADPKD (Zhou et al., 2013). In conclusion, AMPK-activating drugs such as metformin and salsalate are clinically easier to tolerate than mTORC1 inhibitors, making them more promising candidates to control cystogenesis in ADPKD. However, more clinical trials are needed.
AMP-activated protein kinase interacts with other processes relevant to the pathophysiology of autosomal dominant polycystic kidney disease
In addition to modulating cell proliferation and fluid secretion, AMPK regulates other processes that have been shown to be abnormal in ADPKD, such as mitochondrial structure and function, the peroxisome proliferator-activated receptor α (PPARα) pathway, and the innate immune response (Figure 2). (Song et al., 2020)
The kidney displays mitochondrial abnormalities in both obesity and autosomal dominant polycystic kidney disease
Strong evidence indicates that AMPK promotes mitochondrial biogenesis by activating peroxisome proliferator-activated receptor γ coactivator-1 α (PGC-1α) (Steinberg and Kemp, 2009). As a transcriptional coactivator, PGC1α interacts with nuclear respiratory factors 1 and 2 (NRF1 and NRF2), which regulate mitochondrial transcription factor A (TFAM), the latter playing a crucial role in maintaining mitochondrial DNA transcription and replication. (Figure 2). (Kelly and Scarpula, 2004; Reznick and Shulman, 2006)
Mitochondrial dysfunction, presumably related to insulin resistance, is present in obesity, affecting tissues that participate in nutrient metabolism such as the adipose tissue, liver, and skeletal muscle (Bournat and Brown, 2010; Montgomery and Turner, 2015). The progressive enlargement of white adipose tissue in mice and humans can impair blood flow and result in hypoxia, which can lead to macrophage recruitment and infiltration (Wood et al., 2009). In turn, inflammation, in addition to excessive food intake, may increase the production of reactive oxygen species, causing mitochondrial dysfunction, although there is also evidence the latter may in fact precede adipose tissue inflammation (Lahera et al., 2017; de Mello et al., 2018; Woo et al., 2019). Increased mitochondrial fission, defective mitochondrial biogenesis and oxidative capacity, and intracellular triglyceride overload have been described in the adipose tissue, liver, and skeletal muscle of obese rodents and humans (Bournat and Brown, 2010; de Mello et al., 2018). In the kidney specifically, mitochondrial abnormalities have been inconsistently described in ob/ob mice and mice with HFD-induced obesity (Declèves et al., 2014; Szeto et al., 2016). Liraglutide restored AMPK and PGC-1α signaling in the kidneys of HFD-fed rats, and inhibited the formation of mitochondrial reactive oxygen species (Wang et al., 2018). There is also evidence that SS-31, an antioxidant that protects the structure of mitochondrial cristae, may prevent the renal toxicity, including mitochondrial damage, caused by fatty acid accumulation (Szeto et al., 2016).
The role of mitochondria in the pathophysiology of ADPKD has been covered in depth in several recent reviews (Padovano et al., 2018; Menezes and Germino, 2019; Nowak and Hopp, 2020; Podrini et al., 2020). Briefly, mitochondrial abnormalities can be found in Pkd1 knock-out kidney epithelial cells isolated from mice, in mouse and rat models of polycystic kidney disease, and in kidney tissues from patients with ADPKD (Ishimoto et al., 2017; Lin et al., 2018). Morphological changes on electron microscopy include swelling and fragmentation of the mitochondria, and damaged cristae. These morphological changes in mitochondria, suggestive of defects in mitophagy, are very analogous to those observed in mice deficient for AMPK in muscle and brown adipose tissue (Bujak et al., 2015; Mottillo et al., 2016). Moreover, the mitochondrial DNA copy number decreases from an early stage of ADPKD, in parallel with kidney mRNA and protein expression of PGC-1α (Ishimoto et al., 2017). Several studies have highlighted that the impairment of mitochondrial metabolic processes such as fatty acid oxidation and oxidative phosphorylation drives cyst formation, in part via reduced PPARα expression (Menezes et al., 2012; Rowe et al., 2013; Menezes et al., 2016; Hajarnis et al., 2017; Padovano et al., 2017; Podrini et al., 2018). Because of defective fatty acid oxidation, a higher fat intake aggravated the kidney cyst burden in a non-orthologous rat and two orthologous mouse models of polycystic kidney disease (Jayapalan et al., 2000; Menezes et al., 2016). Since PC1 and PC2 appear to affect both the morphology and function of mitochondria, mitochondrial dysfunction might be one of the original molecular events preceding metabolic dysregulation in ADPKD (Padovano et al., 2017; Lin et al., 2018; Kuo et al., 2019).
Peroxisome proliferator-activated receptor α activation ameliorates lipid-induced toxicity in the kidney
AMPK phosphorylates, thereby activating, PGC-1α, which acts as a transcriptional coactivator of PPARα (Figure 2). (Vega et al., 2000; Steinberg and Kemp, 2009) The AMPKα subunit can also coactivate PPARα independently of its kinase activity (Bronner et al., 2004). This ligand-activated transcription factor binds to fatty acids to regulate essential metabolic responses to fasting, including ketogenesis in the liver and fatty acid utilization in multiple tissues such as the kidney (Kersten et al., 1999; Guan, 2002; Wang, 2010). In a mouse model of HFD-induced glomerular injury, treatment with the PPARα agonist fenofibrate increased the expression of lipolytic enzymes, reducing lipid accumulation and oxidative stress in the glomeruli, and preventing glomerular fibrosis (Tanaka et al., 2011). The network comprising PPARα and its gene targets is known to be downregulated in mouse models of ADPKD and human cysts, and PPARα downregulation is in part responsible for the intrinsic defect in fatty acid oxidation seen in ADPKD (Hajarnis et al., 2017; Lakhia et al., 2018; Lakhia, 2020). One mechanism underlying PPARα downregulation may be post-transcriptional inhibition by the microRNAs miR-17–92 and miR-21, which are upregulated in mouse and human ADPKD (Lakhia et al., 2016; Hajarnis et al., 2017). Using fenofibrate improved the phenotype of both aggressive and slowly progressive mouse models of ADPKD, and ameliorated the tubulointerstitial fibrosis associated with reduced fatty acid oxidation (Table 1). (Kang et al., 2015; Hajarnis et al., 2017; Lakhia et al., 2018) However, although fibrates are commonly used in the treatment of dyslipidemia, their long-term safety in kidney disease remains unclear (Jun et al., 2012; Melissa et al., 2020).
Chronic inflammation is a feature of obesity and autosomal dominant polycystic kidney disease
Both obesity and ADPKD are associated with a state of low-grade chronic inflammation. While other immune components participate in the inflammatory phenotype in both conditions, macrophages have been most extensively studied and play a dominant role (Zimmerman et al., 2020). In obesity, the upregulation of monocyte chemoattractant protein 1 (MCP-1) in fat depots with resulting accumulation of macrophages is crucial to induce inflammation in the adipose tissue (Oh et al., 2012; Amano et al., 2014). In humans, increased circulating MCP-1 correlates with higher levels of other inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), but also obesity, waist circumference, and the homeostatic model assessment for insulin resistance (HOMA-IR) score (Kim et al., 2006). Studies in obese mice support the causal role for MCP-1-mediated macrophage accumulation in adipose tissue in promoting insulin resistance (Kamei et al., 2006; Kanda et al., 2006; Weisberg et al., 2006; Aouadi et al., 2013; Kim et al., 2016). Interestingly, macrophage AMPKβ1 appears to blunt the inflammatory response to saturated fatty acids by increasing fatty acid oxidation (Galic et al., 2011).
In patients with ADPKD, the inflammatory markers MCP-1 and macrophage migration inhibitory factor (MIF) are elevated in the urine and cyst fluid (Zheng et al., 2003; Meijer et al., 2010; Kim and Tam, 2011; Chen et al., 2015). Urinary MCP-1 correlates with TKV and predicts progression to CKD stage 3 (Meijer et al., 2010; Chapman et al., 2012; Messchendorp et al., 2018; Segarra-Medrano et al., 2020). In an inducible knock-out model of Pkd1, MCP-1 upregulation, independently of tubular injury, caused monocyte infiltration. Monocytes differentiated into pro-inflammatory M1-like macrophages that accumulated around cysts, causing oxidative damage and tubular injury; a switch to alternatively activated M2-like macrophages then coincided with increased cyst proliferation (Cassini et al., 2018). In fact, most interstitial macrophages in the kidneys of patients with ADPKD were found to be M2-like, and human cyst cells were shown to promote M2-like macrophage polarization in vitro by secreting soluble factors including lactates (Swenson-Fields et al., 2013; Yang et al., 2018). M2-like macrophages, normally involved in tissue repair, are likely locked in a maladaptive cycle of pro-proliferative and pro-fibrotic activity (Weimbs, 2018). Previous work reported that global macrophage depletion with liposomal clodronate slowed kidney disease progression in non-orthologous and orthologous mice (Karihaloo et al., 2011; Swenson-Fields et al., 2013; Yang et al., 2018). Moreover, attenuating macrophage accumulation in Pkd1-deficient mice with Mcp1 knock-out or an antagonist of the MCP-1 receptor (also known as CCR2) reduced cyst growth and tubular injury (Cassini et al., 2018; Viau et al., 2018).
Importantly, the proinflammatory cytokine MIF is associated on the one hand with increases in MCP-1, tumor necrosis factor α (TNF-α), and macrophage accumulation, and on the other hand with increased glucose uptake and glycolytic gene expression, inhibition of AMPK activity, and activation of ERK and mTOR signaling (Chen et al., 2015). Its deletion or pharmacologic inhibition has reversed these abnormalities and slowed disease progression in multiple Pkd1-deficient murine models (Chen et al., 2015). As an additional link between kidney inflammation and metabolic disease, LKB1 forms a complex with PC1 to suppress the expression of MCP-1 in tubular epithelia; the tubular deletion of Lkb1 or Pkd1 restores MCP-1 expression and causes monocyte/CCR2+ macrophage recruitment (Viau et al., 2018). This is notable because ciliary LKB1 colocalizes with and activates AMPK (Boehlke et al., 2010; Mick et al., 2015). Thus, similarly to MIF, LKB1 appears to be an upstream regulator of both inflammatory and metabolic changes in ADPKD.
Conclusion
The pathobiology of ADPKD is strongly linked to metabolic dysregulation, which may be secondary to mitochondrial abnormalities induced by defective polycystin function. Pathways common to both obesity-related kidney disease and ADPKD suggest that obesity with ectopic lipid deposition in the kidneys may contribute to the progression of cystic disease through various mechanisms, notably through inhibition of AMPK activity. Overweight and obesity are frequent in patients with ADPKD, and weight loss should be beneficial for both conditions (Pickel et al., 1093; Nowak et al., 2018). Further work will be needed to understand if and how weight loss can attenuate cystogenesis on a molecular level. In addition to dietary changes, pharmacological activation of AMPK may attenuate lipid-related kidney injury as well as the cystic burden. The repurposing of metabolic drugs to treat patients with ADPKD has seen limited development thus far. Nevertheless, based on promising in vivo data, it is reasonable to believe that well-known and relatively safe pharmacological agents such as metformin or salsalate, both of which activate AMPK, could attenuate lipid-induced nephrotoxicity and reduce cystic disease severity. Given the slow progression of human ADPKD, using pharmacological agents that are safe and tolerable will be critical.
Statements
Author contributions
I-AI wrote the different versions of the manuscript, with help from LP and guidance from XS, YP, GS, and H-KS. LP, XS, AH, JS, H-KS, GS, and YP helped to revise the manuscript. All authors approve the final version of this manuscript.
Funding
I-AI was supported by a KRESCENT fellowship (KRES170001) (Kidney Foundation of Canada) from 2017 to 2020 and holds a 2021–2022 Queen Elizabeth II/Dr. Arnie Aberman Graduate Scholarship in Science and Technology (University of Toronto).
Acknowledgments
We would like to thank Christina Beharry for helping edit parts of the manuscript. Copyright-free art from Wikimedia Commons and Open Clip Art was used to design Figure 3.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abarca-GómezL.AbdeenZ. A.HamidZ. A.Abu-RmeilehN. M.Acosta-CazaresB.AcuinC.et al (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet390 (10113), 2627–2642. 10.1016/S0140-6736(17)32129-3
2
AlbertiK. G. M. M.EckelR. H.GrundyS. M.ZimmetP. Z.CleemanJ. I.DonatoK. A.et al (2009). Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation120 (16), 1640–1645. 10.1161/CIRCULATIONAHA.109.192644
3
AmanoS. U.CohenJ. L.VangalaP.TencerovaM.NicoloroS. M.YaweJ. C.et al (2014). Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell. Metab.19 (1), 162–171. 10.1016/j.cmet.2013.11.017
4
AndersonK.WherleL.ParkM.NelsonK.NguyenL. (2014). Salsalate, an old, inexpensive drug with potential new indications: A review of the evidence from 3 recent studies. Am. Health Drug Benefits7 (4), 231–235.
5
AouadiM.TencerovaM.VangalaP.YaweJ. C.NicoloroS. M.AmanoS. U.et al (2013). Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice. Proc. Natl. Acad. Sci. U. S. A.110 (20), 8278–8283. 10.1073/pnas.1300492110
6
BaldwinS. A.BarrosL. F.GriffithsM.IngramJ.RobbinsE. C.StreetsA. J.et al (1997). Regulation of GLUT1 in response to cellular stress.Biochem. Soc. Trans.25 (3), 954–958. 10.1042/bst0250954
7
BandyopadhyayG. K.YuJ. G.OfrecioJ.OlefskyJ. M. (2006). Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes55 (8), 2277–2285. 10.2337/db06-0062
8
BarnesB. R.RyderJ. W.SteilerT. L.FryerL. G. D.CarlingD.ZierathJ. R. (2002). Isoform-specific regulation of 5′ AMP-activated protein kinase in skeletal muscle from obese zucker ( fa/fa ) rats in response to contraction. Diabetes51 (9), 2703–2708. 10.2337/diabetes.51.9.2703
9
BaruaM.CilO.PatersonA. D.WangK.HeN.DicksE.et al (2009). Family history of renal disease severity predicts the mutated gene in ADPKD. J. Am. Soc. Nephrol.20 (8), 1833–1838. 10.1681/ASN.2009020162
10
BoehlkeC.KotsisF.PatelV.BraegS.VoelkerH.BredtS.et al (2010). Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat. Cell. Biol.12 (11), 1115–1122. 10.1038/ncb2117
11
BournatJ. C.BrownC. W. (2010). Mitochondrial dysfunction in obesity. Curr. Opin. Endocrinol. Diabetes Obes.17 (5), 446–452. 10.1097/MED.0b013e32833c3026
12
BoutoujaF.StiehmC. M.PlattaH. W. (2019). mTOR: A cellular regulator interface in Health and disease. Cells8 (1), 18. 10.3390/cells8010018
13
BraunW. E.ScholdJ. D.StephanyB. R.SpirkoR. A. (2014). Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: An open-label randomized controlled pilot study.Clin. J. Am. Soc. Nephrol.9 (5), 881–888. 10.2215/CJN.02650313
14
BronnerM.HertzR.Bar-TanaJ. (2004). Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor α by AMP-activated protein kinase. Biochem. J.384 (2), 295–305. 10.1042/BJ20040955
15
BrosnahanG. M.WangW.GitomerB.StruemphT.GeorgeD.YouZ.et al (2022). Metformin therapy in autosomal dominant polycystic kidney disease: A feasibility study. Am. J. Kidney Dis.79, 518–526. 10.1053/j.ajkd.2021.06.026
16
BujakA. L.CraneJ. D.LallyJ. S.FordR. J.KangS. J.RebalkaI. A.et al (2015). AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell. Metab.21 (6), 883–890. 10.1016/j.cmet.2015.05.016
17
CassiniM. F.KakadeV. R.KurtzE.SulkowskiP.GlazerP.TorresR.et al (2018). Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol.29 (10), 2471–2481. 10.1681/ASN.2018050518
18
ChangM. Y.MaT. L.HungC. C.TianY. C.ChenY. C.YangC. W.et al (2017). Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci. Rep.7 (1), 7161. 10.1038/s41598-017-07300-x
19
ChapmanA. B.BostJ. E.TorresV. E.Guay-WoodfordL.BaeK. T.LandsittelD.et al (2012). Kidney volume and functional Outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol.7 (3), 479–486. 10.2215/CJN.09500911
20
ChenL.ZhouX.FanL. X.YaoY.Swenson-FieldsK. I.GadjevaM.et al (2015). Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J. Clin. Investig.125 (6), 2399–2412. 10.1172/JCI80467
21
ChiaravalliM.RoweI.MannellaV.QuiliciG.CanuT.BianchiV.et al (2016). 2-Deoxy-d-Glucose ameliorates PKD progression. J. Am. Soc. Nephrol.27 (7), 1958–1969. 10.1681/ASN.2015030231
22
Cornec-Le GallE.AudrézetM. P.ChenJ. M.HourmantM.MorinM. P.PerrichotR.et al (2013). Type of PKD1 mutation influences renal outcome in ADPKD. J. Am. Soc. Nephrol.24 (6), 1006–1013. 10.1681/ASN.2012070650
23
de MelloA. H.CostaA. B.EngelJ. D. G.RezinG. T. (2018). Mitochondrial dysfunction in obesity. Life Sci.192, 26–32. 10.1016/j.lfs.2017.11.019
24
DeclèvesA. E.MathewA. V.CunardR.SharmaK. (2011). AMPK mediates the initiation of kidney disease induced by a high-fat diet. J. Am. Soc. Nephrol.22 (10), 1846–1855. 10.1681/ASN.2011010026
25
DeclèvesA. E.ZolkipliZ.SatrianoJ.WangL.NakayamaT.RogacM.et al (2014). Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury.Kidney Int.85 (3), 611–623. 10.1038/ki.2013.462
26
DistefanoG.BocaM.RoweI.WodarczykC.MaL.PiontekK. B.et al (2009). Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol. Cell. Biol.29 (9), 2359–2371. 10.1128/MCB.01259-08
27
FallT.MendelsonM.SpeliotesE. K. (2017). Recent advances in human genetics and epigenetics of adiposity: Pathway to precision medicine?Gastroenterology152 (7), 1695–1706. 10.1053/j.gastro.2017.01.054
28
FraserS.MountP.HillR.LevidiotisV.KatsisF.StapletonD.et al (2005). Regulation of the energy sensor AMP-activated protein kinase in the kidney by dietary salt intake and osmolality. Am. J. Physiol. Ren. Physiol.288 (3), F578–F586. 10.1152/ajprenal.00190.2004
29
GaddeK. M.MartinC. K.BerthoudH. R.HeymsfieldS. B. (2018). Obesity: Pathophysiology and Management.Obes. J. Am. Coll. Cardiol.71 (1), 69–84. 10.1016/j.jacc.2017.11.011
30
GalicS.FullertonM. D.SchertzerJ. D.SikkemaS.MarcinkoK.WalkleyC. R.et al (2011). Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Investig.121 (12), 4903–4915. 10.1172/JCI58577
31
GranthamJ. J. (2008). Clinical practice. Autosomal dominant polycystic kidney disease.N. Engl. J. Med.359, 1477–1485. 10.1056/NEJMcp0804458
32
GuanY. (2002). Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease. Minerva Urol. Nefrol.54 (2), 65–79.
33
HajarnisS.LakhiaR.YheskelM.WilliamsD.SorourianM.LiuX.et al (2017). microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism. Nat. Commun.8 (1), 14395. 10.1038/ncomms14395
34
HallowsK. R.MountP. F.Pastor-SolerN. M.PowerD. A. (2010). Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am. J. Physiol. Ren. Physiol.298 (5), F1067–F1077. 10.1152/ajprenal.00005.2010
35
HardieD. G.RossF. A.HawleyS. A. (2012). Ampk: A nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell. Biol.13 (4), 251–262. 10.1038/nrm3311
36
HarrisP. C.TorresV. E. (2009). Polycystic kidney disease. Annu. Rev. Med.60, 321–337. 10.1146/annurev.med.60.101707.125712
37
HaumannS.MüllerR. U.LiebauM. C. (2020). Metabolic changes in polycystic kidney disease as a potential target for systemic treatment. Int. J. Mol. Sci.21 (17), 6093. 10.3390/ijms21176093
38
HeyerC. M.SundsbakJ. L.AbebeK. Z.ChapmanA. B.TorresV. E.GranthamJ. J.et al (2016). Predicted mutation strength of nontruncating PKD1 Mutations aids genotype-phenotype correlations in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol.27 (9), 2872–2884. 10.1681/ASN.2015050583
39
HwangY. H.ConklinJ.ChanW.RoslinN. M.LiuJ.HeN.et al (2016). Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol.27 (6), 1861–1868. 10.1681/ASN.2015060648
40
IrazabalM. V.TorresV. E.HoganM. C.GlocknerJ.KingB. F.OfstieT. G.et al (2011). Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int.80 (3), 295–301. 10.1038/ki.2011.119
41
IshimotoY.InagiR.YoshiharaD.KugitaM.NagaoS.ShimizuA.et al (2017). Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell. Biol.37 (24), e00337-17. 10.1128/MCB.00337-17
42
JayapalanS.SaboorianM. H.EdmundsJ. W.AukemaH. M. (2000). High dietary fat intake increases renal cyst disease progression in han:SPRD-cy rats. J. Nutr.130 (9), 2356–2360. 10.1093/jn/130.9.2356
43
JiangP.RenL.ZhiL.YuZ.LvF.XuF.et al (2021). Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53. Mol. Cell.81 (3), 629–637.e5. e5. 10.1016/j.molcel.2020.12.008
44
JunM.ZhuB.TonelliM.JardineM. J.PatelA.NealB.et al (2012). Effects of fibrates in kidney disease: A systematic review and meta-analysis. J. Am. Coll. Cardiol.60 (20), 2061–2071. 10.1016/j.jacc.2012.07.049
45
KameiN.TobeK.SuzukiR.OhsugiM.WatanabeT.KubotaN.et al (2006). Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem.281 (36), 26602–26614. 10.1074/jbc.M601284200
46
KandaH.TateyaS.TamoriY.KotaniK.HiasaK. i.KitazawaR.et al (2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig.116 (6), 1494–1505. 10.1172/JCI26498
47
KangH. M.AhnS. H.ChoiP.KoY. A.HanS. H.ChingaF.et al (2015). Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development.Nat. Med.21 (1), 37–46. 10.1038/nm.3762
48
KarihalooA.KoraishyF.HuenS. C.LeeY.MerrickD.CaplanM. J.et al (2011). Macrophages promote cyst growth in polycystic kidney disease. J. Am. Soc. Nephrol.22 (10), 1809–1814. 10.1681/ASN.2011010084
49
KellyD. P.ScarpulaR. C. (2004). Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes. Dev.18 (4), 357–368. 10.1101/gad.1177604
50
KerstenS.SeydouxJ.PetersJ. M.GonzalezF. J.DesvergneB.WahliW. (1999). Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Investig.103 (11), 1489–1498. 10.1172/JCI6223
51
KimC. S.ParkH. S.KawadaT.KimJ. H.LimD.HubbardN. E.et al (2006). Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes.30 (9), 1347–1355. 10.1038/sj.ijo.0803259
52
KimJ.ChungK.ChoiC.BeloorJ.UllahI.KimN.et al (2016). Silencing CCR2 in macrophages alleviates adipose tissue inflammation and the associated metabolic syndrome in dietary obese mice. Mol. Ther. Nucleic Acids5, e280. 10.1038/mtna.2015.51
53
KimM. J.TamF. W. K. (2011). Urinary monocyte chemoattractant protein-1 in renal disease. Clin. Chim. Acta.412 (23), 2022–2030. 10.1016/j.cca.2011.07.023
54
KimM. Y.LimJ. H.YounH. H.HongY. A.YangK. S.ParkH. S.et al (2013). Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK–SIRT1–PGC1α axis in db/db mice. Diabetologia56 (1), 204–217. 10.1007/s00125-012-2747-2
55
KuoI. Y.BrillA. L.LemosF. O.JiangJ. Y.FalconeJ. L.KimmerlingE. P.et al (2019). Polycystin 2 regulates mitochondrial Ca 2+ signaling, bioenergetics, and dynamics through mitofusin 2. Sci. Signal.12 (580), eaat7397. 10.1126/scisignal.aat7397
56
LaheraV.de las HerasN.López-FarréA.ManuchaW.FerderL. (2017). Role of mitochondrial dysfunction in hypertension and obesity. Curr. Hypertens. Rep.19 (2), 11. 10.1007/s11906-017-0710-9
57
LakhiaR.HajarnisS.WilliamsD.AboudehenK.YheskelM.XingC.et al (2016). MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease. J. Am. Soc. Nephrol.27 (8), 2319–2330. 10.1681/ASN.2015060634
58
LakhiaR. (2020). The role of PPARα in autosomal dominant polycystic kidney disease. Curr. Opin. Nephrol. Hypertens.29 (4), 432–438. 10.1097/MNH.0000000000000615
59
LakhiaR.YheskelM.FlatenA.Quittner-StromE. B.HollandW. L.PatelV. (2018). PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice. Am. J. Physiol. Ren. Physiol.314 (1), F122–F131. 10.1152/ajprenal.00352.2017
60
LanktreeM. B.HaghighiA.GuiardE.IliutaI. A.SongX.HarrisP. C.et al (2018). Prevalence estimates of polycystic kidney and liver disease by population sequencing. J. Am. Soc. Nephrol.29 (10), 2593–2600. 10.1681/ASN.2018050493
61
LaplanteM.SabatiniD. M. (2012). mTOR signaling in growth control and disease. Cell.149 (2), 274–293. 10.1016/j.cell.2012.03.017
62
LeeE. J.SeoE.KimJ. W.NamS. A.LeeJ. Y.JunJ.et al (2020). TAZ/Wnt-β-catenin/c-MYC axis regulates cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A.117 (46), 29001–29012. 10.1073/pnas.2009334117
63
LeonhardW. N.SongX.KanhaiA. A.IliutaI. A.BozovicA.SteinbergG. R.et al (2019). Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease. EBioMedicine47, 436–445. 10.1016/j.ebiom.2019.08.041
64
LianX.WuX.LiZ.ZhangY.SongK.CaiG.et al (2019). The combination of metformin and 2‐deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. Br. J. Pharmacol.176 (5), 711–724. 10.1111/bph.14558
65
LianX.ZhaoJ.WuX.ZhangY.LiQ.LinS.et al (2017). The changes in glucose metabolism and cell proliferation in the kidneys of polycystic kidney disease mini-pig models. Biochem. Biophys. Res. Commun.488 (2), 374–381. 10.1016/j.bbrc.2017.05.060
66
LinC. C.KurashigeM.LiuY.TerabayashiT.IshimotoY.WangT.et al (2018). A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci. Rep.8 (1), 2743. 10.1038/s41598-018-20856-6
67
MartinT. L.AlquierT.AsakuraK.FurukawaN.PreitnerF.KahnB. B. (2006). Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J. Biol. Chem.281 (28), 18933–18941. 10.1074/jbc.M512831200
68
MeijerE.BoertienW. E.NautaF. L.BakkerS. J. L.van OeverenW.RookM.et al (2010). Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis. Am. J. Kidney Dis.56 (5), 883–895. 10.1053/j.ajkd.2010.06.023
69
MelissaS.CynthiaJ.ElaniS. (2020). Abstract 104: Mortality risk across chronic kidney disease stages with fibrate or niacin use compared with No fibrate or niacin therapy in male US veterans. Circ. Cardiovasc. Qual. Outcomes13 (1), A104. 10.1161/hcq.13.suppl_1.104
70
MenezesL. F.GerminoG. G. (2019). The pathobiology of polycystic kidney disease from a metabolic viewpoint. Nat. Rev. Nephrol.15 (12), 735–749. 10.1038/s41581-019-0183-y
71
MenezesL. F.LinC. C.ZhouF.GerminoG. G. (2016). Fatty acid oxidation is impaired in an orthologous mouse model of autosomal dominant polycystic kidney disease. EBioMedicine5, 183–192. 10.1016/j.ebiom.2016.01.027
72
MenezesL. F.ZhouF.PattersonA. D.PiontekK. B.KrauszK. W.GonzalezF. J.et al (2012). Network analysis of a pkd1-mouse model of autosomal dominant polycystic kidney disease identifies HNF4α as a disease modifier. PLoS Genet.8 (11), e1003053. 10.1371/journal.pgen.1003053
73
MesschendorpA. L.MeijerE.BoertienW. E.EngelsG. E.CasteleijnN. F.SpithovenE. M.et al (2018). Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression. Kidney Int. Rep.3 (2), 291–301. 10.1016/j.ekir.2017.10.004
74
MickD. U.RodriguesR. B.LeibR. D.AdamsC. M.ChienA. S.GygiS. P.et al (2015). Proteomics of primary cilia by proximity labeling. Dev. Cell.35 (4), 497–512. 10.1016/j.devcel.2015.10.015
75
MontgomeryM. K.TurnerN. (2015). Mitochondrial dysfunction and insulin resistance: An update. Endocr. Connect.4 (1), R1–R15. 10.1530/EC-14-0092
76
MottilloE. P.DesjardinsE. M.CraneJ. D.SmithB. K.GreenA. E.DucommunS.et al (2016). Lack of adipocyte AMPK exacerbates insulin resistance and hepatic steatosis through Brown and beige adipose tissue function. Cell. Metab.24 (1), 118–129. 10.1016/j.cmet.2016.06.006
77
NCD Risk Factor Collaboration (2016). Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet387 (10026), 1377–1396. 10.1016/S0140-6736(16)30054-X
78
NowakK. L.HoppK. (2020). Metabolic reprogramming in autosomal dominant polycystic kidney disease: Evidence and therapeutic potential.Clin. J. Am. Soc. Nephrol.15 (4), 577–584. 10.2215/cjn.13291019
79
NowakK. L.SteeleC.GitomerB.WangW.OuyangJ.ChoncholM. B. (2021). Overweight and obesity and progression of ADPKD. Clin. J. Am. Soc. Nephrol.16 (6), 908–915. 10.2215/CJN.16871020
80
NowakK. L.YouZ.GitomerB.BrosnahanG.TorresV. E.ChapmanA. B.et al (2018). Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol.29 (2), 571–578. 10.1681/ASN.2017070819
81
OhD. Y.MorinagaH.TalukdarS.BaeE. J.OlefskyJ. M. (2012). Increased macrophage migration into adipose tissue in obese mice. Diabetes61 (2), 346–354. 10.2337/db11-0860
82
OsthusR. C.ShimH.KimS.LiQ.ReddyR.MukherjeeM.et al (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-myc. J. Biol. Chem.275 (29), 21797–21800. 10.1074/jbc.C000023200
83
PadovanoV.KuoI. Y.StavolaL. K.AerniH. R.FlahertyB. J.ChapinH. C.et al (2017). The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function. Most. KE, Ed. MBoC.28 (2), 261–269. 10.1091/mbc.e16-08-0597
84
PadovanoV.PodriniC.BolettaA.CaplanM. J. (2018). Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat. Rev. Nephrol.14 (11), 678–687. 10.1038/s41581-018-0051-1
85
PadwalR. S.GabrR. Q.SharmaA. M.LangkaasL. A.BirchD. W.KarmaliS.et al (2011). Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care34 (6), 1295–1300. 10.2337/dc10-2140
86
Pastor-SolerN. M.LiH.PhamJ.RiveraD.HoP. Y.MancinoV.et al (2022). Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am. J. Physiol. Ren. Physiol.322 (1), F27–F41. 10.1152/ajprenal.00298.2021
87
PericoN.AntigaL.CaroliA.RuggenentiP.FasoliniG.CafaroM.et al (2010). Sirolimus therapy to halt the progression of ADPKD. J. Am. Soc. Nephrol.21 (6), 1031–1040. 10.1681/ASN.2009121302
88
PerroneR. D.AbebeK. Z.WatnickT. J.AlthouseA. D.HallowsK. R.LalamaC. M.et al (2021). Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD). Kidney Int.100, 684–696. 10.1016/j.kint.2021.06.013
89
PickelL.IliutaI. A.ScholeyJ.PeiY.SungH. K.. Dietary interventions in autosomal dominant polycystic kidney disease. Adv. Nutr.. 10.1093/advances/nmab131
90
Pietrzak-NowackaM.SafranowK.ByraE.Bińczak-KuletaA.CiechanowiczA.CiechanowskiK. (2009). Metabolic syndrome components in patients with autosomal-dominant polycystic kidney disease. Kidney Blood Press. Res.32 (6), 405–410. 10.1159/000260042
91
PodriniC.CassinaL.BolettaA. (2020). Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell. Signal.67, 109495. 10.1016/j.cellsig.2019.109495
92
PodriniC.RoweI.PagliariniR.CostaA. S. H.ChiaravalliM.Di MeoI.et al (2018). Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways. Commun. Biol.1 (1), 194. 10.1038/s42003-018-0200-x
93
ReedB.HelalI.McFannK.WangW.YanX. D.SchrierR. W. (2012). The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol. Dial. Transpl.27 (7), 2862–2865. 10.1093/ndt/gfr744
94
RenaG.HardieD. G.PearsonE. R. (2017). The mechanisms of action of metformin. Diabetologia60 (9), 1577–1585. 10.1007/s00125-017-4342-z
95
ReznickR. M.ShulmanG. I. (2006). The role of AMP-activated protein kinase in mitochondrial biogenesis: AMPK in mitochondrial biogenesis. J. Physiol.574 (1), 33–39. 10.1113/jphysiol.2006.109512
96
RiegerspergerM.HerknerH.Sunder-PlassmannG. (2015). Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (vienna RAP study): Study protocol for a randomized controlled trial. Trials16 (1), 182. 10.1186/s13063-015-0692-3
97
RiwantoM.KapoorS.RodriguezD.EdenhoferI.SegererS.WüthrichR. P. (2016). Inhibition of aerobic glycolysis attenuates disease progression in polycystic kidney disease. PLoS One11 (1), e0146654. 10.1371/journal.pone.0146654
98
RosenE. D.SpiegelmanB. M. (2006). Adipocytes as regulators of energy balance and glucose homeostasis. Nature444 (7121), 847–853. 10.1038/nature05483
99
RossettiS.ConsugarM. B.ChapmanA. B.TorresV. E.Guay-WoodfordL. M.GranthamJ. J.et al (2007). Comprehensive molecular Diagnostics in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol.18 (7), 2143–2160. 10.1681/ASN.2006121387
100
RoweI.BolettaA. (2014). Defective metabolism in polycystic kidney disease: Potential for therapy and open questions. Nephrol. Dial. Transpl.29 (8), 1480–1486. 10.1093/ndt/gft521
101
RoweI.ChiaravalliM.MannellaV.UlisseV.QuiliciG.PemaM.et al (2013). Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med.19 (4), 488–493. 10.1038/nm.3092
102
RuggenentiP.GentileG.PericoN.PernaA.BarcellaL.TrilliniM.et al (2016). Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4. Clin. J. Am. Soc. Nephrol.11 (5), 785–794. 10.2215/CJN.09900915
103
SalattoC. T.MillerR. A.CameronK. O.CokorinosE.ReyesA.WardJ.et al (2017). Selective activation of AMPK β 1-containing isoforms improves kidney function in a rat model of diabetic nephropathy. J. Pharmacol. Exp. Ther.361 (2), 303–311. 10.1124/jpet.116.237925
104
SchrierR. W.McFannK. K.JohnsonA. M. (2003). Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int.63 (2), 678–685. 10.1046/j.1523-1755.2003.00776.x
105
Segarra-MedranoA.MartinM.AgrazI.VilaprinyoM.ChamounB.JatemE.et al (2020). Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease. Clin. Kidney J.13, 607–612. 10.1093/ckj/sfz105
106
SerraA. L.PosterD.KistlerA. D.KrauerF.RainaS.YoungJ.et al (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med.363 (9), 820–829. 10.1056/NEJMoa0907419
107
ShillingfordJ. M.MurciaN. S.LarsonC. H.LowS. H.HedgepethR.BrownN.et al (2006). The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A.103 (14), 5466–5471. 10.1073/pnas.0509694103
108
ShillingfordJ. M.PiontekK. B.GerminoG. G.WeimbsT. (2010). Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol.21 (3), 489–497. 10.1681/ASN.2009040421
109
SongX.TsakiridisE.SteinbergG. R.PeiY. (2020). Targeting AMP-activated protein kinase (AMPK) for treatment of autosomal dominant polycystic kidney disease. Cell. Signal.73, 109704. 10.1016/j.cellsig.2020.109704
110
SorohanB. M.IsmailG.AndronesiA.MicuG.ObrișcaB.JurubițaR.et al (2019). A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease. BMC Nephrol.20 (1), 276. 10.1186/s12882-019-1463-2
111
SriwijitkamolA.IvyJ. L.Christ-RobertsC.DeFronzoR. A.MandarinoL. J.MusiN. (2006). LKB1-AMPK signaling in muscle from obese insulin-resistant Zucker rats and effects of training. Am. J. Physiol. Endocrinol. Metab.290 (5), E925–E932. 10.1152/ajpendo.00429.2005
112
SteinbergG. R.CarlingD. (2019). AMP-Activated protein kinase: The current landscape for drug development. Nat. Rev. Drug Discov.18 (7), 527–551. 10.1038/s41573-019-0019-2
113
SteinbergG. R.KempB. E. (2009). AMPK in Health and disease. Physiol. Rev.89 (3), 1025–1078. 10.1152/physrev.00011.2008
114
SteinbergG. R.MichellB. J.van DenderenB. J. W.WattM. J.CareyA. L.FamB. C.et al (2006). Tumor necrosis factor α-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell. Metab.4 (6), 465–474. 10.1016/j.cmet.2006.11.005
115
SteinbergG. R.SmithA. C.van DenderenB. J. W.ChenZ.MurthyS.CampbellD. J.et al (2004). AMP-activated protein kinase is not down-regulated in human skeletal muscle of obese females. J. Clin. Endocrinol. Metab.89 (9), 4575–4580. 10.1210/jc.2004-0308
116
Swenson-FieldsK. I.VivianC. J.SalahS. M.PedaJ. D.DavisB. M.van RooijenN.et al (2013). Macrophages promote polycystic kidney disease progression. Kidney Int.83 (5), 855–864. 10.1038/ki.2012.446
117
SzetoH. H.LiuS.SoongY.AlamN.PruskyG. T.SeshanS. V. (2016). Protection of mitochondria prevents high-fat diet–induced glomerulopathy and proximal tubular injury. Kidney Int.90 (5), 997–1011. 10.1016/j.kint.2016.06.013
118
The GBD 2015 Obesity CollaboratorsAshkan AfshinM. D.MohammadH. F.MarissaB. R.Patrick SurB. A.Kara EstepM. P. A.Alex LeeB. A.et al (2017). Health effects of overweight and obesity in 195 countries over 25 years. N. Engl. J. Med.377 (1), 13–27. 10.1056/NEJMoa1614362
119
TakiarV.NishioS.Seo-MayerP.KingJ. D.JrLiH.ZhangL.et al (2011). Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc. Natl. Acad. Sci. U. S. A.108 (6), 2462–2467. 10.1073/pnas.1011498108
120
TanakaY.KumeS.ArakiS. ichiIsshikiK.Chin-KanasakiM.SakaguchiM.et al (2011). Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis. Kidney Int.79 (8), 871–882. 10.1038/ki.2010.530
121
TaoY.KimJ.SchrierR. W.EdelsteinC. L. (2005). Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol.16 (1), 46–51. 10.1681/ASN.2004080660
122
ThomasG. V.TranC.MellinghoffI. K.WelsbieD. S.ChanE.FuegerB.et al (2006). Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med.12 (1), 122–127. 10.1038/nm1337
123
TorresV. E.ChapmanA. B.DevuystO.GansevoortR. T.GranthamJ. J.HigashiharaE.et al (2012). Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med.367 (25), 2407–2418. 10.1056/NEJMoa1205511
124
TorresV. E.ChapmanA. B.DevuystO.GansevoortR. T.PerroneR. D.KochG.et al (2017). Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med.377 (20), 1930–1942. 10.1056/NEJMoa1710030
125
ValentineR. J.CoughlanK. A.RudermanN. B.SahaA. K. (2014). Insulin inhibits AMPK activity and phosphorylates AMPK Ser⁴⁸⁵/⁴⁹¹ through Akt in hepatocytes, myotubes and incubated rat skeletal muscle.Arch. Biochem. Biophys.562, 62–69. 10.1016/j.abb.2014.08.013
126
van HerpenN. A.Schrauwen-HinderlingV. B. (2008). Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav.94 (2), 231–241. 10.1016/j.physbeh.2007.11.049
127
Vander HeidenM. G.CantleyL. C.ThompsonC. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science324 (5930), 1029–1033. 10.1126/science.1160809
128
VegaR. B.HussJ. M.KellyD. P. (2000). The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol.20 (5), 1868–1876. 10.1128/MCB.20.5.1868-1876.2000
129
ViauA.BienaiméF.LukasK.TodkarA. P.KnollM.YakulovT. A.et al (2018). Cilia‐localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney. EMBO J.37 (15), e98615. 10.15252/embj.201798615
130
WahlP. R.SerraA. L.Le HirM.MolleK. D.HallM. N.WüthrichR. P. (2006). Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transpl.21 (3), 598–604. 10.1093/ndt/gfi181
131
WalzG.BuddeK.MannaaM.NurnbergerJ.WannerC.SommererC.et al (2010). Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med.363 (9), 830–840. 10.1056/NEJMoa1003491
132
WangC.LiL.LiuS. (2018). “GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis,”. Editor JolesJ. A., 13, e0193473. 10.1371/journal.pone.0193473PLoS ONE3
133
WangY. X. (2010). PPARs: Diverse regulators in energy metabolism and metabolic diseases. Cell. Res.20 (2), 124–137. 10.1038/cr.2010.13
134
WangyunM.UngerR. H. (2005). Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone. Am. J. Physiol. Endocrinol. Metab.288 (1), E216–E221. 10.1152/ajpendo.00004.2004
135
WarnerG.HeinK. Z.NinV.EdwardsM.ChiniC. C. S.HoppK.et al (2016). Food restriction ameliorates the development of polycystic kidney disease. J. Am. Soc. Nephrol.27 (5), 1437–1447. 10.1681/ASN.2015020132
136
WeimbsT. (2018). Are cyst-associated macrophages in polycystic kidney disease the equivalent to TAMs in cancer?J. Am. Soc. Nephrol.29 (10), 2447–2448. 10.1681/ASN.2018080846
137
WeisbergS. P.HunterD.HuberR.LemieuxJ.SlaymakerS.VaddiK.et al (2006). CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Investig.116 (1), 115–124. 10.1172/JCI24335
138
WooC. Y.JangJ. E.LeeS. E.KohE. H.LeeK. U. (2019). Mitochondrial dysfunction in adipocytes as a primary cause of adipose tissue inflammation. Diabetes Metab. J.43 (3), 247–256. 10.4093/dmj.2018.0221
139
WoodI. S.de HerediaF. P.WangB.TrayhurnP. (2009). Cellular hypoxia and adipose tissue dysfunction in obesity: Symposium on ‘Frontiers in adipose tissue biology. Proc. Nutr. Soc.68 (4), 370–377. 10.1017/S0029665109990206
140
WuM.WahlP. R.Le HirM.Wäckerle-MenY.WüthrichR. P.SerraA. L. (2007). Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res.30 (4), 253–259. 10.1159/000104818
141
YamaharaK.KumeS.KoyaD.TanakaY.MoritaY.Chin-KanasakiM.et al (2013). Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J. Am. Soc. Nephrol.24 (11), 1769–1781. 10.1681/ASN.2012111080
142
YamamotoT.TakabatakeY.TakahashiA.KimuraT.NambaT.MatsudaJ.et al (2017). High-fat diet–induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. J. Am. Soc. Nephrol.28 (5), 1534–1551. 10.1681/ASN.2016070731
143
YangY.ChenM.ZhouJ.LvJ.SongS.FuL.et al (2018). Interactions between macrophages and cyst-lining epithelial cells promote kidney cyst growth in pkd1-deficient mice. J. Am. Soc. Nephrol.29 (9), 2310–2325. 10.1681/ASN.2018010074
144
YoonM. S. (2017). The role of mammalian target of rapamycin (mTOR) in insulin signaling. Nutrients9 (11), 1176. 10.3390/nu9111176
145
YuX.McCorkleS.WangM.LeeY.LiJ.SahaA. K.et al (2004). Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: Prevention of diabetes and ectopic lipid deposition. Diabetologia47 (11), 2012–2021. 10.1007/s00125-004-1570-9
146
ZafarI.BelibiF. A.HeZ.EdelsteinC. L. (2009). Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). Nephrol. Dial. Transpl.24 (8), 2349–2353. 10.1093/ndt/gfp129
147
ZafarI.RavichandranK.BelibiF. A.DoctorR. B.EdelsteinC. L. (2010). Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int.78 (8), 754–761. 10.1038/ki.2010.250
148
ZhaoP.WongK.ReillyS. M.UhmM.LiaoZ.SunX.et al (2018). TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell.172 (4), 731–743.e12. e12. 10.1016/j.cell.2018.01.007
149
ZhengB.JeongJ. H.AsaraJ. M.YuanY. Y.GranterS. R.ChinL.et al (2009). Oncogenic B-raf negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol. Cell.33 (2), 237–247. 10.1016/j.molcel.2008.12.026
150
ZhengD.WolfeM.CowleyB. D.WallaceD. P.YamaguchiT.GranthamJ. J. (2003). Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol.14 (10), 2588–2595. 10.1097/01.ASN.0000088720.61783.19
151
ZhouX.FanL. X.SweeneyW. E.DenuJ. M.AvnerE. D.LiX. (2013). Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease. J. Clin. Investig.123 (7), 3084–3098. 10.1172/JCI64401
152
ZimmermanK. A.HoppK.MrugM. (2020). Role of chemokines, innate and adaptive immunity. Cell. Signal.73, 109647. 10.1016/j.cellsig.2020.109647
Summary
Keywords
autosomal dominant polycystic kidney disease, energy metabolism, obesity, metabolic dysregulation, AMPK
Citation
Iliuta I-A, Song X, Pickel L, Haghighi A, Retnakaran R, Scholey J, Sung H-K, Steinberg GR and Pei Y (2022) Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease. Front. Mol. Biosci. 9:962933. doi: 10.3389/fmolb.2022.962933
Received
06 June 2022
Accepted
21 July 2022
Published
23 August 2022
Volume
9 - 2022
Edited by
Michael Caplan, Yale University, United States
Reviewed by
Nuria M. Pastor-Soler, University of Southern California, United States
Shigeo Horie, Juntendo University, Japan
Updates
Copyright
© 2022 Iliuta, Song, Pickel, Haghighi, Retnakaran, Scholey, Sung, Steinberg and Pei.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: York Pei, york.pei@uhn.ca
This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.